Abstract
To discuss the potential benefit of a chemotherapy regimen including etoposide (etoposide, cisplatin, epirubicin [EPE]), the authors report a single-institutional experience regarding 13 children with hepatoblastoma (HB) and 7 with hepatocellular carcinoma (HCC). Chemotherapy achieved partial response in 8/9 HB and in 4/5 HCC. Eight initially unresectable HB subsequently had liver resection. Event-free survival and overall survival at 5 years were 84 and 88% for HB (non-metastatic cases: 91 and 100%), 29% for HCC. EPE chemotherapy seems to be effective in the treatment of childhood malignant liver tumors. Etoposide could be suggested as part of intensive multidrug regimens for HCC and high-risk HB.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma, Hepatocellular / diagnosis
-
Carcinoma, Hepatocellular / drug therapy*
-
Child
-
Child, Preschool
-
Cisplatin / administration & dosage*
-
Cisplatin / adverse effects
-
Epirubicin / administration & dosage*
-
Epirubicin / adverse effects
-
Etoposide / administration & dosage*
-
Etoposide / adverse effects
-
Female
-
Follow-Up Studies
-
Hepatoblastoma / diagnosis
-
Hepatoblastoma / drug therapy*
-
Humans
-
Infant
-
Liver Neoplasms / diagnosis
-
Liver Neoplasms / drug therapy*
-
Male
-
Survival Analysis
-
Treatment Outcome
Substances
-
Epirubicin
-
Etoposide
-
Cisplatin